Search

Supplemental material, sj-docx-1-pch-10.1177_21501351231174828 for Activated Prothrombin Complex Concentrate in Pediatric Cardiac Patients, Our Early Experience by Elena Ashikhmina Swan, Nathan J. Brinkman, Brian D. Lahr, Michael E. Nemergut, Joseph A. Dearani and Elizabeth H. Stephens in World Journal for Pediatric and Congenital Heart Surgery

Supplemental material, sj-docx-1-pch-10.1177_21501351231174828 for Activated Prothrombin Complex Concentrate in Pediatric Cardiac Patients, Our Early Experience by Elena Ashikhmina Swan, Nathan J. Brinkman, Brian D. Lahr, Michael E. Nemergut, Joseph A. Dearani and Elizabeth H. Stephens in World Journal for Pediatric and Congenital Heart Surgery

Propylene glycol (PG) is a solvent commonly used in medications that, while benign at low doses, may cause toxicity in adults and children at high doses. We describe a case and the physiologic sequelae of propylene glycol toxicity manifested in a critically ill adolescent male with refractory myoclonic status epilepticus aggressively treated with multiple PG-containing medications (lorazepam, phenobarbital, and pentobarbital)—all within accepted dosing guidelines and a total daily PG exposure previously recognized to be safe. Hemodynamic measurements by bedside echocardiography during clinical toxicity are also reported. Clinicians should have a high index of suspicion for propylene glycol toxicity in patients treated with PG-containing medications even when the total PG exposure is lower than currently accepted limits.